NEURONETICS INC (STIM) Stock Price, Quote, News and Overview
NASDAQ:STIM - Nasdaq - US64131A1051 - Common Stock - Currency: USD
STIM Quote, Performance and Key Statistics
4.58
+0.12 (+2.69%)
The current stock price of STIM is 4.58 USD. In the past month the price increased by 27.22%. In the past year, price increased by 20.21%.
STIM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 27.79 | 230.35B | ||
| ISRG | INTUITIVE SURGICAL INC | 69.3 | 189.75B | ||
| BSX | BOSTON SCIENTIFIC CORP | 38.86 | 155.20B | ||
| SYK | STRYKER CORP | 30.19 | 144.36B | ||
| MDT | MEDTRONIC PLC | 15.89 | 108.82B | ||
| BDX | BECTON DICKINSON AND CO | 11.98 | 48.46B | ||
| EW | EDWARDS LIFESCIENCES CORP | 29.1 | 44.47B | ||
| IDXX | IDEXX LABORATORIES INC | 41.39 | 38.24B | ||
| RMD | RESMED INC | 26.43 | 35.18B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.33 | 32.29B | ||
| DXCM | DEXCOM INC | 49.47 | 32.00B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.3 | 24.05B |
Related stock screener links
About STIM
Company Profile
Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. The company is headquartered in Malvern, Pennsylvania and currently employs 716 full-time employees. The company went IPO on 2018-06-28. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The firm provides more than 7.1 million treatments to over 1,95,000 patients.
Company Info
NEURONETICS INC
3222 Phoenixville Pike
Malvern PENNSYLVANIA 19355 US
CEO: Keith J. Sullivan
Employees: 716
Phone: 18776007555
NEURONETICS INC / STIM FAQ
What is the stock price of NEURONETICS INC today?
The current stock price of STIM is 4.58 USD. The price increased by 2.69% in the last trading session.
What is the ticker symbol for NEURONETICS INC stock?
The exchange symbol of NEURONETICS INC is STIM and it is listed on the Nasdaq exchange.
On which exchange is STIM stock listed?
STIM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NEURONETICS INC stock?
10 analysts have analysed STIM and the average price target is 6.97 USD. This implies a price increase of 52.18% is expected in the next year compared to the current price of 4.58. Check the NEURONETICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NEURONETICS INC worth?
NEURONETICS INC (STIM) has a market capitalization of 301.41M USD. This makes STIM a Small Cap stock.
How many employees does NEURONETICS INC have?
NEURONETICS INC (STIM) currently has 716 employees.
What are the support and resistance levels for NEURONETICS INC (STIM) stock?
NEURONETICS INC (STIM) has a support level at 4.39 and a resistance level at 4.59. Check the full technical report for a detailed analysis of STIM support and resistance levels.
Is NEURONETICS INC (STIM) expected to grow?
The Revenue of NEURONETICS INC (STIM) is expected to grow by 105.76% in the next year. Check the estimates tab for more information on the STIM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NEURONETICS INC (STIM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of STIM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of STIM, evaluating the profitability, health, valuation and growth aspects
- NEURONETICS INC (STIM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NEURONETICS INC (STIM) Sales and EPS estimates to see what analysts future expectations are.
- NEURONETICS INC (STIM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NEURONETICS INC (STIM) Insider and Institutional Ownership to learn about the owners and their transactions.
- NEURONETICS INC (STIM) Stock Chart to make your own analysis
- NEURONETICS INC (STIM) Latest news and press-releases to stay up to date.
Does NEURONETICS INC (STIM) stock pay dividends?
STIM does not pay a dividend.
When does NEURONETICS INC (STIM) report earnings?
NEURONETICS INC (STIM) will report earnings on 2025-05-06, before the market open.
What is the Price/Earnings (PE) ratio of NEURONETICS INC (STIM)?
NEURONETICS INC (STIM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.37).
What is the Short Interest ratio of NEURONETICS INC (STIM) stock?
The outstanding short interest for NEURONETICS INC (STIM) is 9.47% of its float. Check the ownership tab for more information on the STIM short interest.
STIM Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to STIM. When comparing the yearly performance of all stocks, STIM is one of the better performing stocks in the market, outperforming 94.57% of all stocks.
STIM Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to STIM. STIM may be in some trouble as it scores bad on both profitability and health.
STIM Financial Highlights
Over the last trailing twelve months STIM reported a non-GAAP Earnings per Share(EPS) of -1.37. The EPS decreased by -28.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.02% | ||
| ROE | -157.76% | ||
| Debt/Equity | 1.99 |
STIM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to STIM. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 76.55% and a revenue growth 105.76% for STIM